Robuta

Sponsor of the Day: Jerkmate
https://juvlabs.com/our-pipeline/ Our Pipeline - Juvenescence Jan 16, 2025 - CORE MEDICINES PIPELINE Leading Healthspan Innovations Our core medicines (JuvTherapeutics) are comprised of therapeutics developed by the Juvenescence team,... pipelinejuvenescence https://www.amherstindy.org/tag/juvenescence/ Juvenescence - Amherst Indy amherst indyjuvenescence https://juvlabs.com/science/ Science - Juvenescence Oct 1, 2024 - SCIENTIFIC APPROACH What Causes Aging? We base our work on breakthrough scientific discoveries that target the underlying biological causes of aging. 85% of... sciencejuvenescence https://juvlabs.com/our-team/jim-mellon/ Jim Mellon - Juvenescence Oct 9, 2024 - Jim MellonDeputy Chairman / Co-Founder Jim Mellon, a co-founder and Deputy Chairman of Juvenescence, was inspired by the possibilities and advances being made... jimmellonjuvenescence https://juvlabs.com/ Biotech Company - Juvenescence Jan 6, 2026 - We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases. biotech companyjuvenescence https://juvlabs.com/news/ News - Juvenescence Oct 1, 2024 - In the News Press Releases All newsjuvenescence https://juvlabs.com/news/press-releases/juvenescence-completes-phase-1-trial-of-pai-1-inhibitor/ Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor - Juvenescence Feb 26, 2026 - Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517)... phase 1juvenescencecompletestrialpai